CD4 and Kaposi's sarcoma: Reduced importance of CD4 cell count at enrolment in HAART users vs non-users was also seen in the SHCS for non-Hodgkin's lymphoma, but the impact of HAART on non-Hodgkin's lymphoma was weaker (HR, 0.26; 95% CI, 0.20–0.33) than on KS, and, hence, non-Hodgkin's lymphoma incidence (1.9; 95% CI, 1.6–2.6 per 1000 py) became higher than KS incidence among HAART users (Polesel et al, 2008).